JP2016510594A - Ｔリンパ球におけるヘパラナーゼの発現 - Google Patents

Ｔリンパ球におけるヘパラナーゼの発現 Download PDF

Info

Publication number
JP2016510594A
JP2016510594A JP2015561628A JP2015561628A JP2016510594A JP 2016510594 A JP2016510594 A JP 2016510594A JP 2015561628 A JP2015561628 A JP 2015561628A JP 2015561628 A JP2015561628 A JP 2015561628A JP 2016510594 A JP2016510594 A JP 2016510594A
Authority
JP
Japan
Prior art keywords
cell
cells
heparanase
car
hpse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015561628A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510594A5 (https=
Inventor
ドッティ、ジャンピエトロ
マルケッティ、ダリオ
カルアーナ、イニャツィオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of JP2016510594A publication Critical patent/JP2016510594A/ja
Publication of JP2016510594A5 publication Critical patent/JP2016510594A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01166—Heparanase (3.2.1.166)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
JP2015561628A 2013-03-05 2014-03-05 Ｔリンパ球におけるヘパラナーゼの発現 Ceased JP2016510594A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361772591P 2013-03-05 2013-03-05
US61/772,591 2013-03-05
PCT/US2014/020936 WO2014138315A1 (en) 2013-03-05 2014-03-05 Heparanase expression in human t lymphocytes

Publications (2)

Publication Number Publication Date
JP2016510594A true JP2016510594A (ja) 2016-04-11
JP2016510594A5 JP2016510594A5 (https=) 2017-04-06

Family

ID=50397277

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015561628A Ceased JP2016510594A (ja) 2013-03-05 2014-03-05 Ｔリンパ球におけるヘパラナーゼの発現

Country Status (8)

Country Link
US (1) US20160017302A1 (https=)
EP (1) EP2964253A1 (https=)
JP (1) JP2016510594A (https=)
CN (1) CN105407914A (https=)
AU (1) AU2014225708B2 (https=)
CA (1) CA2904236A1 (https=)
HK (1) HK1220111A1 (https=)
WO (1) WO2014138315A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017214A1 (en) 2013-07-29 2015-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
MX373460B (es) 2014-03-11 2020-04-07 Cellectis Metodo para generar celulas t compatibles para el trasplante alogenico.
JP7086375B2 (ja) 2015-04-23 2022-06-20 ベイラー カレッジ オブ メディスン 生体内での存続性及び治療活性及びその増殖のためのｎｋｔ細胞サブセット
WO2016187459A1 (en) 2015-05-20 2016-11-24 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
JP6949728B2 (ja) * 2015-05-29 2021-10-13 ジュノー セラピューティクス インコーポレイテッド 遺伝子操作された細胞における阻害相互作用を調節するための組成物および方法
MX2018005274A (es) 2015-10-30 2019-09-19 The Regents Of The Universtiy Of California Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t.
WO2017117521A1 (en) * 2015-12-31 2017-07-06 Berkeley Lights, Inc. Tumor infilitrating cells engineered to express a pro-inflammatory polypeptide
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
CA3048645A1 (en) 2016-12-30 2018-07-05 The Regents Of The University Of California Methods for selection and generation of genome edited t cells
EP3600447A4 (en) * 2017-03-20 2020-12-30 Baylor College of Medicine TRANSGENIC C-MPL TO INTRODUCE LIGAND-DEPENDENT CO-STIMULATION AND CYTOKINE SIGNALS INTO GENETICALLY MODIFIED CELLS BY TCR
WO2020123938A1 (en) 2018-12-14 2020-06-18 Bluebird Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
US12291560B2 (en) 2018-12-14 2025-05-06 Regeneron Pharmaceuticals, Inc. Dimerizing agent regulated immunoreceptor complexes
KR20220004751A (ko) 2019-05-04 2022-01-11 인히브릭스, 인크. CLEC12a 결합 폴리펩타이드 및 이의 용도
US12421315B2 (en) 2019-05-08 2025-09-23 Regeneron Pharmaceuticals, Inc. CLL-1 targeted immunotherapies
CN114450397A (zh) * 2019-08-01 2022-05-06 纪念斯隆-凯特琳癌症中心 用于改善免疫疗法的细胞及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001514855A (ja) * 1997-09-02 2001-09-18 インサイトストラテジー アンド マーケティング リミテッド ヘパラナーゼ活性保有ポリペプチドをエンコードするポリヌクレオチドおよび移入細胞での該ポリペプチドの発現
WO2007034480A2 (en) * 2005-09-20 2007-03-29 Carmel-Haifa University Economic Corp. Ltd Heparanases and splice variants thereof, ponucleotides encoding them and uses thereof
WO2012033885A1 (en) * 2010-09-08 2012-03-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered gd2-specific t cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5843728A (en) 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CA2432157A1 (en) * 2000-12-19 2002-06-27 Insight Strategy And Marketing Ltd. The use of ecm degrading enzymes for the improvement of cell transplantation
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
EP4032552B1 (en) 2008-08-26 2023-10-04 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001514855A (ja) * 1997-09-02 2001-09-18 インサイトストラテジー アンド マーケティング リミテッド ヘパラナーゼ活性保有ポリペプチドをエンコードするポリヌクレオチドおよび移入細胞での該ポリペプチドの発現
WO2007034480A2 (en) * 2005-09-20 2007-03-29 Carmel-Haifa University Economic Corp. Ltd Heparanases and splice variants thereof, ponucleotides encoding them and uses thereof
WO2012033885A1 (en) * 2010-09-08 2012-03-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered gd2-specific t cells

Also Published As

Publication number Publication date
HK1220111A1 (zh) 2017-04-28
CA2904236A1 (en) 2014-09-12
WO2014138315A8 (en) 2018-07-26
AU2014225708B2 (en) 2018-10-18
CN105407914A (zh) 2016-03-16
AU2014225708A1 (en) 2015-10-08
WO2014138315A1 (en) 2014-09-12
US20160017302A1 (en) 2016-01-21
EP2964253A1 (en) 2016-01-13

Similar Documents

Publication Publication Date Title
JP7549055B2 (ja) メラノーマ優先発現抗原に対して向けられたｔ細胞レセプターおよびその使用
JP6678215B2 (ja) がんにおけるｃｄ１３８の標的化
JP2016510594A (ja) Ｔリンパ球におけるヘパラナーゼの発現
US11725061B2 (en) CSGP4—specific chimeric antigen receptor for cancer
ES2795023T3 (es) Reconocimiento específico del microambiente tumoral mediante el uso de células NKT manipuladas
JP2017536812A (ja) バイパータイト型およびトリパータイト型のシグナル伝達免疫細胞
JP2016513458A (ja) 化学療法耐性免疫細胞
JP2018500337A (ja) 炭酸脱水酵素ｉｘ特異的キメラ抗原受容体およびその使用方法
US20200016207A1 (en) TRANSGENIC c-MPL PROVIDES LIGAND-DEPENDENT CO-STIMULATION AND CYTOKINE SIGNALS TO TCR-ENGINEERED T CELLS
HK1249424B (en) T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180815

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190115

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20190524